A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers

Hee Chang Jang, Choong Jong Kim, Kye Hyoung Kim, Kwang Hee Lee, Young Ho Byun, Baik Lin Seong, Giulietta Saletti, Cecil Czerkinsky, Wan Beom Park, Sang Won Park, Hong Bin Kim, Nam Joong Kim, Myoung don Oh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A randomized, double-blind, controlled clinical trial was conducted to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, and to determine its minimum effective dose. The overall rates of cutaneous " take" reaction and humoral and cellular immunogenicity in CJ-50300 vaccinees were 100% (123/123), 99.2% (122/123), and 90.8% (109/120), respectively, and these rates did not differ significantly between the conventional-dose and the low-dose CJ-50300 (1.0×108 and 1.0×107 plaque-forming units/mL, respectively) (P>0.05 for each). No serious adverse reaction was observed. However, one case of possible generalized vaccinia occurred in the conventionally dosed group [ClinicalTrials.gov Identifier: NCT00607243].

Original languageEnglish
Pages (from-to)5845-5849
Number of pages5
JournalVaccine
Volume28
Issue number36
DOIs
Publication statusPublished - 2010 Aug 1

Fingerprint

Smallpox Vaccine
Vaccinia
Controlled Clinical Trials
volunteers
clinical trials
Healthy Volunteers
cell culture
Cell Culture Techniques
vaccines
Safety
Skin
dosage
Vaccinium
immune response

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Jang, Hee Chang ; Kim, Choong Jong ; Kim, Kye Hyoung ; Lee, Kwang Hee ; Byun, Young Ho ; Seong, Baik Lin ; Saletti, Giulietta ; Czerkinsky, Cecil ; Park, Wan Beom ; Park, Sang Won ; Kim, Hong Bin ; Kim, Nam Joong ; Oh, Myoung don. / A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers. In: Vaccine. 2010 ; Vol. 28, No. 36. pp. 5845-5849.
@article{78236f94457f4338b958cc40cdee54f2,
title = "A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers",
abstract = "A randomized, double-blind, controlled clinical trial was conducted to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, and to determine its minimum effective dose. The overall rates of cutaneous {"} take{"} reaction and humoral and cellular immunogenicity in CJ-50300 vaccinees were 100{\%} (123/123), 99.2{\%} (122/123), and 90.8{\%} (109/120), respectively, and these rates did not differ significantly between the conventional-dose and the low-dose CJ-50300 (1.0×108 and 1.0×107 plaque-forming units/mL, respectively) (P>0.05 for each). No serious adverse reaction was observed. However, one case of possible generalized vaccinia occurred in the conventionally dosed group [ClinicalTrials.gov Identifier: NCT00607243].",
author = "Jang, {Hee Chang} and Kim, {Choong Jong} and Kim, {Kye Hyoung} and Lee, {Kwang Hee} and Byun, {Young Ho} and Seong, {Baik Lin} and Giulietta Saletti and Cecil Czerkinsky and Park, {Wan Beom} and Park, {Sang Won} and Kim, {Hong Bin} and Kim, {Nam Joong} and Oh, {Myoung don}",
year = "2010",
month = "8",
day = "1",
doi = "10.1016/j.vaccine.2010.06.063",
language = "English",
volume = "28",
pages = "5845--5849",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "36",

}

Jang, HC, Kim, CJ, Kim, KH, Lee, KH, Byun, YH, Seong, BL, Saletti, G, Czerkinsky, C, Park, WB, Park, SW, Kim, HB, Kim, NJ & Oh, MD 2010, 'A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers', Vaccine, vol. 28, no. 36, pp. 5845-5849. https://doi.org/10.1016/j.vaccine.2010.06.063

A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers. / Jang, Hee Chang; Kim, Choong Jong; Kim, Kye Hyoung; Lee, Kwang Hee; Byun, Young Ho; Seong, Baik Lin; Saletti, Giulietta; Czerkinsky, Cecil; Park, Wan Beom; Park, Sang Won; Kim, Hong Bin; Kim, Nam Joong; Oh, Myoung don.

In: Vaccine, Vol. 28, No. 36, 01.08.2010, p. 5845-5849.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers

AU - Jang, Hee Chang

AU - Kim, Choong Jong

AU - Kim, Kye Hyoung

AU - Lee, Kwang Hee

AU - Byun, Young Ho

AU - Seong, Baik Lin

AU - Saletti, Giulietta

AU - Czerkinsky, Cecil

AU - Park, Wan Beom

AU - Park, Sang Won

AU - Kim, Hong Bin

AU - Kim, Nam Joong

AU - Oh, Myoung don

PY - 2010/8/1

Y1 - 2010/8/1

N2 - A randomized, double-blind, controlled clinical trial was conducted to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, and to determine its minimum effective dose. The overall rates of cutaneous " take" reaction and humoral and cellular immunogenicity in CJ-50300 vaccinees were 100% (123/123), 99.2% (122/123), and 90.8% (109/120), respectively, and these rates did not differ significantly between the conventional-dose and the low-dose CJ-50300 (1.0×108 and 1.0×107 plaque-forming units/mL, respectively) (P>0.05 for each). No serious adverse reaction was observed. However, one case of possible generalized vaccinia occurred in the conventionally dosed group [ClinicalTrials.gov Identifier: NCT00607243].

AB - A randomized, double-blind, controlled clinical trial was conducted to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, and to determine its minimum effective dose. The overall rates of cutaneous " take" reaction and humoral and cellular immunogenicity in CJ-50300 vaccinees were 100% (123/123), 99.2% (122/123), and 90.8% (109/120), respectively, and these rates did not differ significantly between the conventional-dose and the low-dose CJ-50300 (1.0×108 and 1.0×107 plaque-forming units/mL, respectively) (P>0.05 for each). No serious adverse reaction was observed. However, one case of possible generalized vaccinia occurred in the conventionally dosed group [ClinicalTrials.gov Identifier: NCT00607243].

UR - http://www.scopus.com/inward/record.url?scp=77955552937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955552937&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.06.063

DO - 10.1016/j.vaccine.2010.06.063

M3 - Article

C2 - 20600480

AN - SCOPUS:77955552937

VL - 28

SP - 5845

EP - 5849

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 36

ER -